Skip to main content

ORIGINAL RESEARCH article

Front. Bioeng. Biotechnol.
Sec. Biomaterials
Volume 12 - 2024 | doi: 10.3389/fbioe.2024.1409988
This article is part of the Research Topic Functional Biomaterials for Drug Delivery View all 7 articles

Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of Anlotinib on osteosarcoma

Provisionally accepted
Haoyu Wang Haoyu Wang 1,2Haitian Jiang Haitian Jiang 3*Yining Tao Yining Tao 1,2Jiakang Shen Jiakang Shen 1,2*Haoran Mu Haoran Mu 1,2Chongren Wang Chongren Wang 1,2Xiyu Yang Xiyu Yang 1,2*Zhengdong Cai Zhengdong Cai 1,2*Mu Li Mu Li 4*Wei Sun Wei Sun 1,2*Mengxiong Sun Mengxiong Sun 1,2*
  • 1 Shanghai Jiao Tong University, Shanghai, China
  • 2 Shanghai General Hospital, Shanghai, China
  • 3 State Key Laboratory of Robotics and System, Harbin Institute of Technology, Harbin, Heilongjiang Province, China
  • 4 Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China

The final, formatted version of the article will be published soon.

    Osteosarcoma is a rare malignant tumor with high mortality and disability rates. Its complex genetic background and lack of specific membrane receptors make targeted therapy for osteosarcoma difficult. Therefore, active targeting has become a promising treatment strategy for osteosarcoma.Microrobots can load drugs and travel to the desired target site under precise guidance, thereby enhancing drug efficacy while reducing damage to normal tissues. Tumors overexpressing MET exhibit acquired resistance to VEGFR-targeted drugs. SCR1481B16 is a specific MET inhibitor that has been proven to inhibit MET-driven tumor growth. This study explored the potential of magnetically driven hydrogel robots (MMHR) loaded with SCR1481B1 and Anlotinib in the treatment of Anlotinib-resistant osteosarcoma. We designed and produced microrobots that can precisely deliver drugs to tumor sites under the guidance of magnetic field, while evaluating the effect of enhancing tumor sensitivity to Anlotinib, providing new insights for the treatment of drugresistant osteosarcoma. The clinical application of this method awaits further in-depth research and validation. In conclusion, magnetically driven hydrogel microrobots loaded with SCR1481B16 provide a novel strategy for enhancing the sensitivity of Anlotinib-resistant osteosarcoma, bringing hope for future clinical applications.Osteosarcoma is the most common highly malignant bone tumor [1]. The primary treatment method is limb-salvage surgery combined with neoadjuvant chemotherapy. However, up to 90% of patients still develop drug resistance [2,3]. Patients who fail first-line treatment can only rely on second-line chemotherapy or targeted drugs to prolong their lives. However,second-line drugs also lead to

    Keywords: Microrobots, Magnetic-driven, drug delivery system, VEGFR, Met, Osteosarcoma

    Received: 31 Mar 2024; Accepted: 29 Oct 2024.

    Copyright: © 2024 Wang, Jiang, Tao, Shen, Mu, Wang, Yang, Cai, Li, Sun and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Haitian Jiang, State Key Laboratory of Robotics and System, Harbin Institute of Technology, Harbin, Heilongjiang Province, China
    Jiakang Shen, Shanghai General Hospital, Shanghai, 201620, China
    Xiyu Yang, Shanghai General Hospital, Shanghai, 201620, China
    Zhengdong Cai, Shanghai General Hospital, Shanghai, 201620, China
    Mu Li, Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang Province, China
    Wei Sun, Shanghai General Hospital, Shanghai, 201620, China
    Mengxiong Sun, Shanghai General Hospital, Shanghai, 201620, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.